Results 171 to 180 of about 3,164,975 (245)

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off‐label pegylated interferon alpha was the primary treatment option in Europe prior to the introduction of bulevirtide, a first‐in‐class HDV entry inhibitor.
Monica Radu, Margarita Papatheodoridi, Habiba Kamal Khodir, Sabela Lens, Elisabetta Degasperi, Speranta Iacob, Liliana Gheorghe, Katja Steppich, Florin Alexandru Caruntu, Pietro Lampertico, Soo Aleman, Heiner Wedemeyer   +11 more
wiley   +1 more source

Impact of Antiviral Therapy Scale‐Up Among People Who Inject Drugs in Scotland: Regional Evidence of Hepatitis C Virus Elimination

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background Expansion of highly effective direct‐acting antiviral (DAA) treatment for people who inject drugs (PWID) is regarded as essential to achieve hepatitis C virus (HCV) elimination. A decade since the introduction of DAA treatment, we aimed to assess its roll‐out and associated impact in reducing HCV prevalence among PWID in Scotland ...
Norah E. Palmateer, Pantelis Samartsidis, Christopher Biggam, Andrew McAuley, Scott A. McDonald, John Dillon, Stephen T. Barclay, Samantha J. Shepherd, Rory N. Gunson, Monica Desai, Duncan McCormick, Daniela De Angelis, Matthew Hickman, Sharon J. Hutchinson   +13 more
wiley   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

Enhanced Liver Fibrosis Test, FIB‐4 and FibroScan: Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background and Aims Liver fibrosis is a major determinant of liver‐related events (LREs) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Effective stratification based on fibrosis severity is essential for accurate prognosis.
Antonio Liguori, Francesca D'Ambrosio, Giulia Angelini, Consuelo Cefalo, Simone Galletti, Sara Cardinali, Maria Cristina Giustiniani, Giuseppe Marrone, Marco Biolato, Gianludovico Rapaccini, Maurizio Pompili, Antonio Grieco, Tommaso Mazza, Andrea Urbani, Maurizio Sanguinetti, Antonio Gasbarrini, FPG‐UCSC PROMETEO‐ELF substudy Research Group, Luca Miele   +17 more
wiley   +1 more source

Cumulative Metformin Use and Hepatocellular Carcinoma Risk After HCV SVR: A Multicentre Cohort Study

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background Although sustained virological response (SVR) after hepatitis C virus treatment reduces hepatocellular carcinoma (HCC) incidence, residual risk persists. Metformin has been associated with lower HCC risk, but whether cumulative metformin exposure (CME) lowers post‐SVR risk remains unclear.
Henar Calvo‐Sánchez, Lorena Jara‐Fernández, Raquel Encijo‐Heredia, Irene Villarino, Rubén Alvarado, Marta Quiñones‐Calvo, María‐Luisa Gutiérrez, Joaquín Miquel, Miguel Torralba, Myriam Catalá, José Gómez, Sonia Albertos, Óscar Barquero‐Pérez, Conrado Fernández‐Rodríguez, Juan‐Ramón Larrubia   +14 more
wiley   +1 more source

High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background and Aims Chronic hepatitis B virus (HBV) infection is endemic in Uzbekistan. Previous data showed a high prevalence of anti‐hepatitis D virus (HDV) antibodies in HBsAg‐positive individuals. Limited data are available on disease severity, treatment availability and hepatocellular carcinoma (HCC) prevalence in patients with chronic ...
Malika E. Khodjaeva, Aziza S. Khikmatullaeva, Nargiz S. Ibadullaeva, Gulnara K. Khudaykulova, Munisa M. Ilyasova, Kamila U. Eshbayeva, Dildorakhon N. Abdurakhmanova, Helenie Kefalakes, Petra Huber, Michael J. Gebel, Erkin I. Musabaev, Heiner Wedemeyer, Lisa Sandmann   +12 more
wiley   +1 more source

Comparative Impact of Active Versus Passive Surveillance on Hepatitis C Virus Testing Uptake, Diagnosis and Linkage to Care in Low‐ and Middle‐Income Countries: A Systematic Review and Meta‐Analysis

Tropical Medicine &International Health, Volume 31, Issue 8, Page 997-1011, August 2026.
ABSTRACT Background Hepatitis C virus (HCV) infection remains a major global health challenge, particularly in low‐ and middle‐income countries (LMICs), where limited diagnostic access and weak surveillance hinder progress toward the World Health Organization's 2030 elimination targets.
Katekani Precious Motau, Maureen Moyo Chilufya, Nyeleti P. Chauke, Smangaliso Morerwa, Kuhlula Maluleke   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays

Clinica Chimica Acta, 2013
BACKGROUND Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The Elecsys anti-HCV II assay has been recently launched and we aimed to evaluate its performance compared with other widely used methods ...
Ruifeng Yang
exaly   +2 more sources

Evaluation systems for anti-HCV drugs

Advanced Drug Delivery Reviews, 2007
Development of therapeutics for chronic hepatitis C has been hampered by the lack of an efficient cell culture system and a small animal model for the hepatitis C virus (HCV). An RNA replicon system, in which the HCV genome replicates autonomously in cells, and replication competent viruses derived from an HCV genotype 2a JFH1 strain efficiently ...
Yoshiharu Matsuura, Kohji Moriishi
exaly   +3 more sources

Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris

Biochemical and Biophysical Research Communications, 2014
Shinya Satoh, Masanori Ikeda, Hiromichi Dansako   +2 more
exaly   +2 more sources